Daily Deal Round Up: April 13, 2021
SafeGuard Cyber has raised $45m in a Cisco-backed debt and equity round while Pine Labs has paid the same amount to buy portfolio company Fave.
Brii brightens up with IPO plans
The infectious disease drug developer has applied to float in Hong Kong, which will enable the WuXi AppTec-backed 6 Dimensions Capital to exit.
Tend drills into $125m series C
The personalised dental care provider increased its overall funding to almost $200m in a GV-backed series C round.
StoneWise stocks up with $100m
The drug discovery platform developer will support its growth with new funding from investors including SIG and Legend Capital.
Vaccitech shoots for US IPO
Alphabet, Tencent and Gilead Sciences are in line to achieve exits, after the vaccine developer filed to go public on the Nasdaq Global Market.
Artiva activates $100m IPO plans
The NK cancer drug provider has filed to go public in an offering which would enable GC and its GC Labcell subsidiary to exit.
Hologic hoists in Mobidiag
Autobio Diagnostics is set to exit the molecular diagnostic test provider through a purchase by women’s health-focused technology provider Hologic.
Carta Healthcare carves out series A funding
Mass General Brigham’s AI Digital Innovation Fund has chipped into a $17.3m round for the healthcare data technology provider.

Other News

Analysis: Ikena goes public
The oncology drug developer, backed by Bristol Myers Squibb, secured close to $144m in its IPO. This is an exit from a space that has seen much corporate support over the past decade.
Corporate venturing deal net: 5-9 April 2021
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Werewolf Therapeutics chases $100m IPO
The cancer therapeutics developer has filed to float on the Nasdaq Global Market, with Taiho Ventures set to achieve an exit.
NGK kicks off $100m corporate venturing fund
Pegasus Tech Ventures will help the spark plug and ceramic manufacturer back global entrepreneurs working on healthcare, distributed generation and automotive innovation.
Ventus Therapeutics executes $100m series B
GV returned to reinvest in small molecule drug developer Ventus Therapeutics having backed its $60m series A round almost a year ago.
ValenzaBio balances $70m in series A
The Pierre Fabre-backed antibody therapy developer has closed a series A round featuring new and founding investors.

Editor's Picks

Innovation and digitisation mean healthcare is at a tipping point
Feature: artificial intelligence driving disease prevention, digital health enables personalised medicine, investment takes off
23andMe links to Virgin in $3.5bn reverse merger
The corporate-backed genetic testing service is joining forces with an NYSE-listed special purpose acquisition company sponsored by Virgin Group.
Sana Bio plants itself on public markets
The Alphabet-backed immunotherapy developer secured nearly $588m in what was reputedly the largest ever flotation for a preclinical life sciences company.
2021 in Corporate Venturing: A Preview
Micromobility, AI-equipped drug discovery, home fitness and cloud kitchens are among the sectors that look promising in 2021.
test reg